Harrow, Inc. Non Peo Neo Avg Total Comp Amt
Harrow, Inc. (HROW) reported Non Peo Neo Avg Total Comp Amt of $3.56 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-24.
Financial Statements › Notes
ecd:NonPeoNeoAvgTotalCompAmt · last filed 2026-04-24
| Period end | Non Peo Neo Avg Total Comp Amt 12 month |
|---|---|
| 2025-12-31 | $3.56M DEF 14A · filed 2026-04-24 |
| 2024-12-31 | $796.33K DEF 14A · filed 2026-04-24 |
| 2023-12-31 | $6.47M DEF 14A · filed 2026-04-24 |
| 2022-12-31 | $710.64K DEF 14A · filed 2026-04-24 |
| 2021-12-31 | $3.01M DEF 14A · filed 2026-04-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |